AU2022254114A1 - Ceftibuten dosing regimens - Google Patents

Ceftibuten dosing regimens Download PDF

Info

Publication number
AU2022254114A1
AU2022254114A1 AU2022254114A AU2022254114A AU2022254114A1 AU 2022254114 A1 AU2022254114 A1 AU 2022254114A1 AU 2022254114 A AU2022254114 A AU 2022254114A AU 2022254114 A AU2022254114 A AU 2022254114A AU 2022254114 A1 AU2022254114 A1 AU 2022254114A1
Authority
AU
Australia
Prior art keywords
optionally substituted
alkyl
ceftibuten
group
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2022254114A
Other languages
English (en)
Inventor
David C. Griffith
Olga Lomovskaya
Jeffery S. Loutit
Elizabeth E. Morgan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qpex Biopharma Inc
Original Assignee
Qpex Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qpex Biopharma Inc filed Critical Qpex Biopharma Inc
Publication of AU2022254114A1 publication Critical patent/AU2022254114A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2022254114A 2021-04-05 2022-03-31 Ceftibuten dosing regimens Abandoned AU2022254114A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163170936P 2021-04-05 2021-04-05
US63/170,936 2021-04-05
PCT/US2022/071479 WO2022217199A1 (en) 2021-04-05 2022-03-31 Ceftibuten dosing regimens

Publications (1)

Publication Number Publication Date
AU2022254114A1 true AU2022254114A1 (en) 2023-09-21

Family

ID=83545863

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022254114A Abandoned AU2022254114A1 (en) 2021-04-05 2022-03-31 Ceftibuten dosing regimens

Country Status (11)

Country Link
US (1) US20240197750A1 (enExample)
EP (1) EP4319760A4 (enExample)
JP (1) JP2024512793A (enExample)
KR (1) KR20230167077A (enExample)
CN (1) CN117157078A (enExample)
AU (1) AU2022254114A1 (enExample)
BR (1) BR112023020348A2 (enExample)
CA (1) CA3212788A1 (enExample)
MX (1) MX2023011483A (enExample)
TW (1) TW202304430A (enExample)
WO (1) WO2022217199A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017290060B2 (en) 2016-06-30 2021-07-22 Qpex Biopharma, Inc Boronic acid derivatives and therapeutic uses thereof
US12636297B2 (en) 2019-06-19 2026-05-26 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
US12637481B2 (en) 2020-03-18 2026-05-26 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
IL297458A (en) 2020-05-05 2022-12-01 Qpex Biopharma Inc Boronic acid derivatives and their synthesis, polymorphic forms and medicinal uses

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170252351A1 (en) * 2015-01-24 2017-09-07 Wockhardt Limited Antibacterial Compositions
AU2017290060B2 (en) * 2016-06-30 2021-07-22 Qpex Biopharma, Inc Boronic acid derivatives and therapeutic uses thereof
AU2017295866A1 (en) * 2016-07-14 2019-01-17 Achaogen, Inc. Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections
SG11201901658PA (en) * 2016-09-16 2019-04-29 Entasis Therapeutics Ltd Beta-lactamase inhibitor compounds
US10085999B1 (en) * 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
WO2019093450A1 (ja) * 2017-11-10 2019-05-16 塩野義製薬株式会社 ジアザビシクロオクタン誘導体
DK3886798T3 (da) * 2018-11-29 2026-04-20 Basilea Pharmaceutica Int Ag Allschwil Kombinationssammensætninger, som omfatter en beta-lactamase-hæmmer, og anvendelser deraf
US12636297B2 (en) * 2019-06-19 2026-05-26 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
EP4021443A1 (en) * 2019-08-29 2022-07-06 Arixa Pharmaceuticals, Inc. Orally administered combinations of beta-lactam antibiotics and avibactam derivatives for treating bacterial infections

Also Published As

Publication number Publication date
MX2023011483A (es) 2023-10-03
US20240197750A1 (en) 2024-06-20
EP4319760A1 (en) 2024-02-14
TW202304430A (zh) 2023-02-01
WO2022217199A1 (en) 2022-10-13
CN117157078A (zh) 2023-12-01
KR20230167077A (ko) 2023-12-07
CA3212788A1 (en) 2022-10-13
EP4319760A4 (en) 2025-01-08
BR112023020348A2 (pt) 2023-11-21
JP2024512793A (ja) 2024-03-19

Similar Documents

Publication Publication Date Title
US20240197750A1 (en) Ceftibuten dosing regimens
US20010006972A1 (en) Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome
US20240327426A1 (en) Crystalline forms of ceftibuten
EP1443933B1 (en) Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agents
EP0873753A1 (en) Use of NK-1 receptor antagonists for the manufacture of a medicament in the treatment of symptoms of irritable bowel syndrome
JP5339840B2 (ja) 抗ｘｄｒ−ｔｂ薬、抗ｍｄｒ−ｔｂ薬、及び併用抗結核薬
JP3208437B2 (ja) 癌転移抑制剤
CN119233823A (zh) 硼化合物治疗非结核分枝杆菌感染的方法和用途及用于治疗相同疾病的药物组合物
KR100550839B1 (ko) 항균제
JPH0269417A (ja) 精神分裂病治療用組成物
EP1662875A2 (en) Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders
US20120238605A1 (en) Otamixaban for treatment of elderly and renal impaired non-st elevation myocardial infarction patients
JPH0152366B2 (enExample)
AU2021220445B2 (en) Novel medicament for treating hepatic encephalopathy
US20040087513A1 (en) New drug combinations based on sodium channel blockers and magnesium salts
WO2001000217A1 (en) Medicinal compositions for preventing or treating diarrhea
US20240075041A1 (en) Treatment of eosinophilic disorders with avapritinib
EP4591863A1 (en) Method for treating pneumoconiosis
HK40078840A (en) Novel medicament for treating hepatic encephalopathy
WO2018016596A1 (ja) ＰＰＡＲαアゴニストを含有する、肺高血圧症の予防又は治療剤
CA2491217A1 (en) New drug combinations based on sodium channel blockers and magnesium salts
JP2002504934A (ja) ケタンセリンとｌ−カルニチン又はアルカノイルｌ−カルニチンを含むｃｒｐｓの治療のための組成物
JP2000086518A (ja) 血管攣縮の予防・治療剤
JP2000080031A (ja) 抗菌剤
WO1986000017A1 (fr) Medicaments psychotropes et procede de traitement de psychoses

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period